Reproductive rights advocates protest in response to the leaked Supreme Court draft decision to overturn Roe v. Wade on May 3, 2022 in Washington, D.C.
Supreme Court Postpones Crucial Abortion Pill Ruling
"The Supreme Court knows that siding with extreme Trump judges to restrict medication abortion will ignite the biggest political firestorm since Roe v. Wade was overturned," said one advocate.
An anticipated ruling on access to mifespristone, one of two medications used in a majority of abortions in the U.S., was delayed by the U.S. Supreme Court on Wednesday, giving the court until Friday to rule on the availability of the pill.
The court is considering a ruling handed down earlier this month by the 5th Circuit Court of Appeals, which would terminate Food and Drug Administration (FDA) policies adopted in 2016 to improve access to mifepristone. That year, the agency allowed patients to obtain the pill through the mail, retail pharmacies, and telemedicine prescriptions.
If allowed to take effect, the appeals court ruling would also change the FDA's approval of the drug to seven weeks of pregnancy instead of the current 10 weeks.
The appeals court ruling only partially blocked an early decision by right-wing U.S. District Judge Matthew Kacsmaryk, which would entirely suspend the FDA's approval of mifepristone, more than two decades after the drug became legally available.
The FDA and drug companies have warned that even allowing the 5th Circuit Court of Appeals' ruling to go forward would drastically cut access to mifepristone, which has been used by more than 5 million people in the U.S. since its approval.
Reproductive rights groups on Wednesday emphasized that "mifepristone remains available" until at least Friday, while warning that a ruling in favor of the lower courts' decisions will harm millions of people who rely on the medication.
"There is only one acceptable outcome here," said the Guttmacher Institute, a research and policy group.
Supreme Court observers were left to wonder Wednesday evening whether the ruling was delayed to give time to a liberal justice to write a dissent regarding a denial of a stay on the appeals court's decision, or for a conservative justice to dissent against a stay.
NARAL Pro-Choice America President Mini Timmaraju expressed hope that "the anti-choice extremists on the court" will "throw in the towel and accept reality: the science, the facts, and the law are all on the side of legal and accessible medication abortion."
"As this case continues, safe and effective medication abortion with mifepristone in all 50 states remains in peril. The Supreme Court knows that siding with extreme Trump judges to restrict medication abortion will ignite the biggest political firestorm since Roe v. Wade was overturned," said Timmaraju. "The lower courts' decisions have been entirely baseless."
FINAL DAY! This is urgent.
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission from the outset was simple. To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It’s never been this bad out there. And it’s never been this hard to keep us going. At the very moment Common Dreams is most needed and doing some of its best and most important work, the threats we face are intensifying. Right now, with just hours left in our Spring Campaign, we're still falling short of our make-or-break goal. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Can you make a gift right now to make sure Common Dreams not only survives but thrives? There is no backup plan or rainy day fund. There is only you. —Craig Brown, Co-founder |
An anticipated ruling on access to mifespristone, one of two medications used in a majority of abortions in the U.S., was delayed by the U.S. Supreme Court on Wednesday, giving the court until Friday to rule on the availability of the pill.
The court is considering a ruling handed down earlier this month by the 5th Circuit Court of Appeals, which would terminate Food and Drug Administration (FDA) policies adopted in 2016 to improve access to mifepristone. That year, the agency allowed patients to obtain the pill through the mail, retail pharmacies, and telemedicine prescriptions.
If allowed to take effect, the appeals court ruling would also change the FDA's approval of the drug to seven weeks of pregnancy instead of the current 10 weeks.
The appeals court ruling only partially blocked an early decision by right-wing U.S. District Judge Matthew Kacsmaryk, which would entirely suspend the FDA's approval of mifepristone, more than two decades after the drug became legally available.
The FDA and drug companies have warned that even allowing the 5th Circuit Court of Appeals' ruling to go forward would drastically cut access to mifepristone, which has been used by more than 5 million people in the U.S. since its approval.
Reproductive rights groups on Wednesday emphasized that "mifepristone remains available" until at least Friday, while warning that a ruling in favor of the lower courts' decisions will harm millions of people who rely on the medication.
"There is only one acceptable outcome here," said the Guttmacher Institute, a research and policy group.
Supreme Court observers were left to wonder Wednesday evening whether the ruling was delayed to give time to a liberal justice to write a dissent regarding a denial of a stay on the appeals court's decision, or for a conservative justice to dissent against a stay.
NARAL Pro-Choice America President Mini Timmaraju expressed hope that "the anti-choice extremists on the court" will "throw in the towel and accept reality: the science, the facts, and the law are all on the side of legal and accessible medication abortion."
"As this case continues, safe and effective medication abortion with mifepristone in all 50 states remains in peril. The Supreme Court knows that siding with extreme Trump judges to restrict medication abortion will ignite the biggest political firestorm since Roe v. Wade was overturned," said Timmaraju. "The lower courts' decisions have been entirely baseless."
An anticipated ruling on access to mifespristone, one of two medications used in a majority of abortions in the U.S., was delayed by the U.S. Supreme Court on Wednesday, giving the court until Friday to rule on the availability of the pill.
The court is considering a ruling handed down earlier this month by the 5th Circuit Court of Appeals, which would terminate Food and Drug Administration (FDA) policies adopted in 2016 to improve access to mifepristone. That year, the agency allowed patients to obtain the pill through the mail, retail pharmacies, and telemedicine prescriptions.
If allowed to take effect, the appeals court ruling would also change the FDA's approval of the drug to seven weeks of pregnancy instead of the current 10 weeks.
The appeals court ruling only partially blocked an early decision by right-wing U.S. District Judge Matthew Kacsmaryk, which would entirely suspend the FDA's approval of mifepristone, more than two decades after the drug became legally available.
The FDA and drug companies have warned that even allowing the 5th Circuit Court of Appeals' ruling to go forward would drastically cut access to mifepristone, which has been used by more than 5 million people in the U.S. since its approval.
Reproductive rights groups on Wednesday emphasized that "mifepristone remains available" until at least Friday, while warning that a ruling in favor of the lower courts' decisions will harm millions of people who rely on the medication.
"There is only one acceptable outcome here," said the Guttmacher Institute, a research and policy group.
Supreme Court observers were left to wonder Wednesday evening whether the ruling was delayed to give time to a liberal justice to write a dissent regarding a denial of a stay on the appeals court's decision, or for a conservative justice to dissent against a stay.
NARAL Pro-Choice America President Mini Timmaraju expressed hope that "the anti-choice extremists on the court" will "throw in the towel and accept reality: the science, the facts, and the law are all on the side of legal and accessible medication abortion."
"As this case continues, safe and effective medication abortion with mifepristone in all 50 states remains in peril. The Supreme Court knows that siding with extreme Trump judges to restrict medication abortion will ignite the biggest political firestorm since Roe v. Wade was overturned," said Timmaraju. "The lower courts' decisions have been entirely baseless."